Tuberculosis

©MSF Calls on US pharma corporation Johnson & Johnson to cut key TB drug price in half People with drug-resistant tuberculosis (DR-TB) continue to be deprived of today’s best-possible treatment in part because of high drug prices, according to a new report—DR-TB Drugs Under the Microscope—...
Kasaye sits on his bed in the intensive care unit of the MSF health centre in Abdurafi, a bottle of soda and some cookies in his hands. He looks incredibly frail and the simple acts of drinking and eating seem to require immense effort. “This is the thirteenth time that I have come to MSF for kala...
Urgent need to scale up newer tools available today to save lives; and develop a fast, safe and simple cure for TB As global leaders gather for the first-ever United Nations tuberculosis (TB) Summit in New York this week, Médecins Sans Frontières (MSF)/Doctors Without Borders called on governments...
by Joanne Liu (the international president of Médecins Sans Frontières.) and Paual Farmer (The co-founder of Partners in Health, Professor of Global Health and Social Medicine at Harvard Medical School, and Chief of the Division of Global Health Equity at Brigham and Women’s Hospital.) Though TB...
Despite being curable, the world is losing the battle against tuberculosis (TB). The road ahead is rife with challenges, from diagnosis to treatment, for patients and treatment providers alike. In this Q&A, Dr. Francis Varaine, leader of the MSF working group on Tuberculosis, explains MSF’s...
Dr. Tor Deng is a general practitioner working for MSF in Abyei, a region with special administrative status between Sudan and South Sudan.
Companies and countries must take urgent action to increase access to these life-saving treatments Only 4,800 people with drug-resistant tuberculosis (DR-TB) in 2016 were treated with two newer and much more effective medicines, even though these have now been on the market for up to four years,...
Dr Erlend Grønningen from Trondheim, Norway is MSF’s Inpatient Department Supervising Medical Doctor at Boost Hospital in Lashkar Gah, Helmand.
Two years after two new drugs to treat tuberculosis—the first in over 50 years—were conditionally approved for use, only 2% of the 150,000 people who need them have been able to access them, according to Médecins Sans Frontières (MSF). MSF and other treatment providers are showing that stronger TB...
More than two years after drug approved, only 180 people globally have received it. Geneva, 24 February 2016 Médecins Sans Frontières (MSF) today expressed great concern at the high price announced for the new tuberculosis (TB) drug delamanid. Japanese pharmaceutical company Otsuka said that it...
Subscribe to RSS - Tuberculosis